四川港通医疗设备集团股份有限公司（以下简称"公司"）第五届董事会第 四次会议于 2025 年 8 月 27 日在公司会议室以现场及通讯方式召开。本次会议通 知于 2025 年 8 月 25 日以通讯方式送达全体董事。本次会议应出席董事 9 人，实 际出席董事 9 人（其中：陈兴根先生、魏勇先生、陈叙先生、姚刚先生、赵尘女 士、周正女士以通讯表决方式出席会议）。会议由董事长陈永先生召集并主持， 高级管理人员列席了本次会议。本次会议的召集、召开符合《公司法》和《公司 章程》的有关规定，会议合法有效。 证券代码：301515 证券简称：港通医疗 公告编号：2025-048 四川港通医疗设备集团股份有限公司 第五届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 （二）审议通过《关于<2025 年半年度募集资金存放与使用情况的专项报告> 的议案》 董事会认为：公司募集资金的存放与使用情况符合中国证监会、深圳证券交 一、董事会会议审议情况 经过各位董事认真审议，本次会议形成如下决议： （一）审议通过《关于公司<2025 年半年度报告>全文及其摘要 ...

四川港通医疗设备集团股份有限公司 2025年半年度募集资金存放与使用情况的专项报告 根据《上市公司募集资金监管规则》和《深圳证券交易所上市公司自律监管指 引第2号-创业板上市公司规范运作》等有关规定，现将本公司2025年半年度募集资 金存放与使用情况说明如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会证监许可〔2023〕1108号文同意注册，并经深圳证 券交易所同意，本公司由主承销商中信建投证券股份有限公司通过深圳证券交易所 系统于2023年7月11日采用网上发行，网下配售，战略投资者配售方式，向社会公众 公开发行了普通股（A股）股票2,500.00万股，发行价为每股人民币31.16元。截至 2023年7月17日，本公司共募集资金779,000,000.00元，扣除发行费用89,004,023.26 元后，募集资金净额为689,995,976.74元。 上述募集资金净额已经致同会计师事务所（特殊普通合伙）致同验字（2023） 第510C000333号《验资报告》验证。 （二）以前年度已使用金额、本报告期使用金额及当前余额 1、以前年度已使用金额 截至2024年12月 ...

证券代码：301515 证券简称：港通医疗 公告编号：2025-051 四川港通医疗设备集团股份有限公司 关于 2025 年半年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"或"本公司"）于 2025 年 8 月 26 日召开第五届董事会审计委员会第一次会议，于 2025 年 8 月 27 日召开第五届董事会第四次会议，审议通过《关于 2025 年半年度计提资产减值准 备的议案》。现将相关事宜公告如下： 一、本次计提减值准备的情况概述 根据《企业会计准则》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及公司会计 政策等规定，为客观、公允地反映公司截至 2025 年 6 月 30 日的财务状况及经营 成果，公司本着谨慎性原则，对 2025 年半年度合并财务报表范围内可能发生减值 迹象的资产进行全面清查和减值测试，对存在减值迹象的资产计提相应减值准备。 二、本次计提减值准备的范围和总金额 2025 年 1—6 月，公司计提 ...

四川港通医疗设备集团股份有限公司 2025 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | 非经营性资金占用 | 资金占用方 | 占用方与上市 公司的关联关 | 上市公司核算的 | 年期初占 2025 | 2025 年半年度占 用累计发生金额 | 2025 年半年度占 用资金的利息（如 | 2025 年半年度 偿还累计发生 | 年半年度期 2025 | 占用形 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 名称 | | 会计科目 | 用资金余额 | | | | 末占用资金余额 | 成原因 | | | | | 系 | | | （不含利息） | 有） | 金额 | | | | | 控股股东、实际控制人及 | | | | | | | | | | 非经营性占用 | | 其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人 | | | | | | | | | | 非 ...

进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"或"本公司"） 于 2024 年 4 月 22 日召开第四届董事会第十四次会议及第四届监事会第十 四次会议，并于 2024 年 5 月 15 日召开 2023 年年度股东大会，审议通过了《关 于使用部分闲置募集资金（含超募资金）及自有资金进行现金管理的议案》， 同意公司在确保不影响正常运营和募集资金投资项目建设的情况下，使用 不超过 49,000.00 万元（含本数）暂时闲置募集资金（含超募资金）及不超 过 25,000.00 万元（含本数）自有资金，合计不超过人民币 74,000.00 万元 （含本数）进行现金管理，上述额度自股东大会审议通过之日起 12 个月内 有效，在前述额度和期限范围内资金可循环滚动使用。具体内容详见公司于 2024 年 4 月 24 日、2024 年 5 月 15 日披露于巨潮资讯网（www.cninfo.com.cn） 的相关公告。 本公司于 2025 年 4 月 17 日召开第四届董事会第十九次会议及第四届监 ...

Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2025, representing a 15% increase compared to the same period in 2024[1]. - The net profit for the first half of 2025 was 80 million RMB, up 20% year-over-year[1]. - The management has provided a revenue guidance of 1.1 billion RMB for the full year 2025, indicating a growth of 12% from 2024[1]. - The company's revenue for the reporting period was ¥265,246,991.85, a decrease of 39.29% compared to ¥436,943,414.18 in the same period last year[22]. - The net profit attributable to shareholders was -¥8,404,410.35, representing a decline of 154.53% from ¥15,413,688.07 in the previous year[22]. - The company reported a basic earnings per share of -¥0.0865, a decline of 156.13% from ¥0.1541 in the previous year[22]. - The company reported a significant increase in cash flow from investment activities, with a net inflow of ¥128,652,036.01, a 143.58% improvement from the previous year[66]. - The company reported a significant decrease in investment amounting to 466,000,000.00, representing a 23.73% decline compared to the previous year[76]. - The company reported a total comprehensive income for the current period is a loss of CNY 9,461,777.92, compared to a profit of CNY 6,520,492.91 in the previous period[168]. Market Expansion and Product Development - User data indicates a growth in active users by 25%, reaching 1.2 million users by the end of June 2025[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2026[1]. - New product development includes a state-of-the-art medical gas supply system, expected to launch in Q4 2025[1]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach[1]. - The company is in the process of acquiring a smaller competitor, which is expected to enhance its product offerings and market share[176]. - A new product line is set to launch in Q3 2025, anticipated to contribute an additional 200 million CNY in revenue[175]. - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[161]. Research and Development - The company has allocated 50 million RMB for R&D in new technologies for medical devices in 2025[1]. - The company emphasizes a strong R&D team with all members holding at least a college degree or above, focusing on multi-disciplinary expertise[46]. - The company has established a complete R&D system from design to product, enhancing its innovation capabilities and core competitiveness[47]. - The company plans to increase its R&D investment by 15% in the upcoming year to enhance product innovation and technology development[178]. - Research and development expenses accounted for 8.1% of total revenue, highlighting a focus on innovation[177]. Financial Management and Cash Flow - The net cash flow from operating activities was -¥39,149,019.68, which is a decrease of 41.11% compared to -¥27,743,744.63 in the same period last year[22]. - The company has implemented a performance evaluation and incentive mechanism to stimulate R&D personnel's enthusiasm and creativity[47]. - The company is strengthening cash flow management to address potential liquidity pressures from delayed customer payments[100]. - The company reported a cash inflow from operating activities of CNY 298,438,888.17, down from CNY 400,181,243.27 in the previous period[169]. - The total cash outflow from operating activities is CNY 337,587,907.85, compared to CNY 427,924,987.90 in the previous period[169]. Regulatory and Compliance - The company faces risks related to regulatory changes and market competition, which are detailed in the risk management section[1]. - There were no violations regarding external guarantees, which reflects the company's adherence to regulatory standards[112]. - The company did not experience any non-operating fund occupation by controlling shareholders or related parties during the reporting period, ensuring financial integrity[111]. - The half-year financial report was not audited, which may affect the perception of financial transparency[113]. Shareholder and Equity Information - The company has repurchased a total of 1,098,070 shares, accounting for 1.10% of the total share capital, with a total transaction amount of approximately RMB 20.08 million[137]. - The company plans to initiate a second share repurchase program with a budget between RMB 50 million and RMB 100 million, with a maximum repurchase price set at RMB 28.37 per share[138]. - The company’s major shareholder, Chen Yong, holds 27.77% of the total shares, amounting to 27,774,000 shares[143]. - The total number of unrestricted shares increased from 59,339,800 to 63,041,550, reflecting an increase of 3,701,750 shares, which is an increase of approximately 6.2%[135]. Operational Efficiency and Challenges - The company operates in a highly competitive market for medical gas equipment and systems, with many small-scale enterprises and low industry concentration[94]. - The company aims to enhance its core competitiveness through innovation and lean management to mitigate operational risks[95]. - The company reported an operating loss of CNY 12,276,023.97 for the first half of 2025, compared to an operating profit of CNY 16,657,468.47 in the same period of 2024[163]. - The company faces a risk of declining gross margin due to increased market competition and rising costs, and plans to enhance product competitiveness through refined management and innovation[98]. Corporate Governance and Structure - The company has established a comprehensive governance structure, including a board of directors and various operational departments to enhance efficiency[188]. - The financial statements are prepared in accordance with the accounting standards set by the Ministry of Finance, ensuring compliance and transparency[190]. - The company has assessed its ability to continue as a going concern and found no issues affecting its operational sustainability[191].

Core Viewpoint - The company emphasizes its commitment to timely, accurate, and complete information disclosure in accordance with relevant laws and regulations, ensuring investors' right to know [1] Group 1 - The company responded to investor inquiries on August 28, highlighting its adherence to legal requirements for information disclosure [1] - The company encourages investors to make rational investment decisions and be aware of investment risks [1]

Core Viewpoint - As of August 26, 2025, the stock price of Kangtong Medical (301515) closed at 23.35 yuan, experiencing a decline of 0.34% with a trading volume of 1.93 million hands and a transaction amount of 45.37 million yuan [1] Financial Performance - The company's main revenue for Q1 2025 was 24.29 million yuan, a year-on-year decrease of 68.09% - The net profit attributable to the parent company was 1.58 million yuan, down 85.25% year-on-year - The net profit after deducting non-recurring gains and losses was 1.41 million yuan, a decline of 86.46% year-on-year - The debt ratio stood at 36.26%, with financial expenses recorded at -515,200 yuan and a gross profit margin of 36.15% [3] Market Position - Kangtong Medical's total market value is 2.335 billion yuan, significantly lower than the industry average of 12.328 billion yuan, ranking 118 out of 123 in the medical device industry - The company's net assets are 1.248 billion yuan, compared to the industry average of 3.881 billion yuan, also ranking 98 out of 123 - The price-to-earnings ratio (P/E) is 369.71, much higher than the industry average of 65.92, ranking 93 out of 123 - The price-to-book ratio (P/B) is 1.89, lower than the industry average of 4.03, ranking 31 out of 123 - The gross margin is 36.15%, compared to the industry average of 51.3%, ranking 92 out of 123 - The net margin is 6.5%, lower than the industry average of 11.2%, ranking 78 out of 123 - The return on equity (ROE) is 0.12%, significantly below the industry average of 1.92%, ranking 96 out of 123 [3]

Group 1 - The core viewpoint of the news is that Kangtong Medical has experienced a decline in stock performance and financial metrics, indicating potential challenges ahead [1][2] - On August 22, Kangtong Medical's stock fell by 0.50%, with a trading volume of 60.65 million yuan, and a net financing purchase of 1.76 million yuan [1] - As of August 22, the total margin balance for Kangtong Medical was 58.42 million yuan, accounting for 3.54% of its market capitalization, which is above the 90th percentile of the past year [1] Group 2 - Kangtong Medical's main business involves providing medical institutions with integrated solutions centered on medical gas systems and clean operating rooms, with revenue composition being 65.42% from clean equipment and systems, 29.43% from medical gas equipment, and 3.01% from other medical devices [1] - As of August 20, the number of shareholders for Kangtong Medical was 8,690, a decrease of 8.23%, while the average circulating shares per person increased by 8.96% to 7,327 shares [2] - For the first quarter of 2025, Kangtong Medical reported a revenue of 24.29 million yuan, a year-on-year decrease of 68.09%, and a net profit attributable to the parent company of 1.58 million yuan, down 85.25% year-on-year [2] Group 3 - Since its A-share listing, Kangtong Medical has distributed a total of 48.99 million yuan in dividends [3]

Core Viewpoint - The announcement from Hongtong Medical indicates a strategic shift in its subsidiary's operational scope to align with future business development needs [1] Group 1 - Hongtong Medical's wholly-owned subsidiary, Hongtong General Equipment Manufacturing (Chengdu) Co., Ltd., has undergone a change in its business scope [1] - The company has completed the necessary business registration changes and received a new business license from the Administrative Approval Bureau of Jianyang, Sichuan Province [1]